Clinical trials: Functional MRI
Cerebral Amyloid Angiopathy
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain.
- Trial name
- NCT01821118
- Testing
- Ponezumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Patellar Tendinopathy / Jumpers Knee
Comparison of Ultrasound-guided Electrolysis Therapy vs. Sham Electrolysis in Patients With Patellar Tendinopathy: A Prospective Randomized Study Including MRI and Shear-wave Ultrasound Elastography Imaging
Study Background and Purpose Tendinopathies are common and debilitating musculoskeletal disorders that often lead to chronic pain and reduced mobility.
- Trial name
- NCT06939491
- Testing
- Ultrasound guided electrolysis therapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- Gymna Uniphy
Subject
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
The aim of this functional Magnetic Resonance Imaging (MRI) study is to assess the effect of single dose of F2695 at 75mg on modulation of the cerebral motor network.
- Trial name
- NCT02266966
- Testing
- F2695
- Where
- France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Substance Dependence, Alcohol Dependence
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
This study will compare the effects of GSK598809 and placebo in alcohol dependent volunteers. A placebo is a pill with no drug in it (i.e. dummy drug) but it is made to look exactly like the real drug.
- Trial name
- NCT00908206
- Testing
- GSK598809
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Neural Correlates In Mild Alzheimer's Disease
The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the…
- Trial name
- NCT00477659
- Testing
- Donepezil hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eisai Inc.
Depressive Disorder and Anxiety Disorders
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
- Trial name
- NCT00513565
- Testing
- single dose
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Volunteers
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.
- Trial name
- NCT00526968
- Testing
- EVT 101
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Evotec Neurosciences GmbH
Functional Magnetic Resonance Imaging
A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180)
This study will identify a dose of ferumoxytol that can reliably detect changes in blood flow/volume in response to non-drug stimuli.
- Trial name
- NCT01244282
- Testing
- fMRI with sensory stimulation
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Binge Eating Behaviour, Binge Eating/Loss of Control Eating
Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway
The goal of this clinical trial is to thoroughly explore and ascertain the mechanism of action of the therapy with the EXOMIND (BTL-699-2) device in the treatment of food cravings (serving as an important precipitant to binge…
- Conditions
- Binge Eating Behaviour, Binge Eating/Loss of Control Eating, Food Craving
- Trial name
- NCT07024550
- Testing
- Treatment with BTL-699-2 device, Treatment with BTL-699-2 device with intensity below therapeutic threshold
- Where
- Czechia
- Volunteers
- 8 people
- Sponsor
- BTL Industries Ltd.
Moderate to Severe Chronic Pain
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.
- Trial name
- NCT03802227
- Testing
- NKTR-181, Oxycodone IR
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nektar Therapeutics
Depressive Disorder, Major
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated…
- Trial name
- NCT03854578
- Testing
- BI 1358894, Citalopram
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Dementia
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.
- Trial name
- NCT00887601
- Testing
- MK3134, Donepezil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients
- Trial name
- RESET BRAIN (NCT03977649)
- Testing
- erenumab
- Where
- 5 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Contrast-Enhanced Magnetic Resonance Imaging Detection
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study. The primary objectives are: To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single…
- Trial name
- NCT06657560
- Testing
- HRS-9231
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Smoking
Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms
A single center, double blind, randomized, placebo controlled, two-treatments, two-period crossover study conducted in adult smokers.
- Trial name
- NCT00657020
- Testing
- Nicotine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depression
Prediction of SSRI Treatment in Major Depression.
This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment.
- Trial name
- NCT03670823
- Testing
- SIEMENS PRISMA MRI
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Diabetes Mellitus
The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
Assess pancreatic beta cell function using MR imaging.
- Trial name
- NCT00280085
- Testing
- MR imaging, Glucose clamp, Arginine
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder (MDD)
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.
- Trial name
- NCT05504486
- Testing
- Brexpiprazole
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.